Association of Oral Cavity and Oropharyngeal Cancer Biomarkers in Surgical Drain Fluid With Patient Outcomes | Facial Plastic Surgery | JAMA Otolaryngology–Head & Neck Surgery | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.239.150.57. Please contact the publisher to request reinstatement.
1.
Ang  KK, Harris  J, Wheeler  R,  et al.  Human papillomavirus and survival of patients with oropharyngeal cancer.  N Engl J Med. 2010;363(1):24-35.PubMedGoogle ScholarCrossref
2.
Sturgis  EM, Ang  KK.  The epidemic of HPV-associated oropharyngeal cancer is here: is it time to change our treatment paradigms?  J Natl Compr Canc Netw. 2011;9(6):665-673.PubMedGoogle ScholarCrossref
3.
Stott-Miller  M, Houck  JR, Lohavanichbutr  P,  et al.  Tumor and salivary matrix metalloproteinase levels are strong diagnostic markers of oral squamous cell carcinoma.  Cancer Epidemiol Biomarkers Prev. 2011;20(12):2628-2636.PubMedGoogle ScholarCrossref
4.
Rosenthal  EL, Matrisian  LM.  Matrix metalloproteases in head and neck cancer.  Head Neck. 2006;28(7):639-648.PubMedGoogle ScholarCrossref
5.
Schultze  A, Ben Batalla  I, Riethdorf  S,  et al.  VEGFR-1 expression levels predict occurrence of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma.  Clin Exp Metastasis. 2012;29(8):879-887.PubMedGoogle ScholarCrossref
6.
Huang  YQ, Li  YD, Li  GK, Jin  Z, Ma  J.  The evaluation of basic fibroblast growth factor and fibroblastic growth factor receptor 1 levels in saliva and serum of patients with salivary gland tumor.  DNA Cell Biol. 2012;31(4):520-523.PubMedGoogle ScholarCrossref
7.
Piccirillo  JF.  Importance of comorbidity in head and neck cancer.  Laryngoscope. 2000;110(4):593-602.PubMedGoogle ScholarCrossref
8.
Lee  KD, Lee  HS, Jeon  CH.  Body fluid biomarkers for early detection of head and neck squamous cell carcinomas.  Anticancer Res. 2011;31(4):1161-1167.PubMedGoogle Scholar
9.
Colović  Z, Pesutić-Pisac  V, Poljak  NK, Racić  G, Cikojević  D, Kontić  M.  Expression of matrix metalloproteinase-9 in patients with squamous cell carcinoma of the larynx.  Coll Antropol. 2013;37(1):151-155.PubMedGoogle Scholar
10.
Linkov  F, Lisovich  A, Yurkovetsky  Z,  et al.  Early detection of head and neck cancer: development of a novel screening tool using multiplexed immunobead-based biomarker profiling.  Cancer Epidemiol Biomarkers Prev. 2007;16(1):102-107.PubMedGoogle ScholarCrossref
11.
Zucker  S, Lysik  RM, Zarrabi  MH, Moll  U.  M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer.  Cancer Res. 1993;53(1):140-146.PubMedGoogle Scholar
12.
Garbisa  S, Scagliotti  G, Masiero  L,  et al.  Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy.  Cancer Res. 1992;52(16):4548-4549.PubMedGoogle Scholar
13.
Garzetti  GG, Ciavattini  A, Lucarini  G, Goteri  G, Romanini  C, Biagini  G.  Increased serum 72 KDa metalloproteinase in serous ovarian tumors: comparison with CA 125.  Anticancer Res. 1996;16(4A):2123-2127.PubMedGoogle Scholar
14.
Tadbir  AA, Purshahidi  S, Ebrahimi  H,  et al.  Serum level of MMP-3 in patients with oral squamous cell carcinoma: lack of association with clinico-pathological features.  Asian Pac J Cancer Prev. 2012;13(9):4545-4548.PubMedGoogle ScholarCrossref
15.
Tao  YS, Ma  XY, Chai  DM,  et al.  Overexpression of MMP-1 and VEGF-C is associated with a less favorable prognosis in esophageal squamous cell carcinoma.  Onkologie. 2012;35(11):651-656.PubMedGoogle ScholarCrossref
16.
Wang  WL, Chang  WL, Yeh  YC,  et al.  Concomitantly elevated serum matrix metalloproteinases 3 and 9 can predict survival of synchronous squamous cell carcinoma of the upper aero-digestive tract.  Mol Carcinog. 2013;52(6):438-445.PubMedGoogle ScholarCrossref
17.
Virós  D, Camacho  M, Zarraonandia  I,  et al.  Prognostic role of MMP-9 expression in head and neck carcinoma patients treated with radiotherapy or chemoradiotherapy.  Oral Oncol. 2013;49(4):322-325.PubMedGoogle ScholarCrossref
18.
Fan  HX, Li  HX, Chen  D, Gao  ZX, Zheng  JH.  Changes in the expression of MMP2, MMP9, and ColIV in stromal cells in oral squamous tongue cell carcinoma: relationships and prognostic implications.  J Exp Clin Cancer Res. 2012;31:90.PubMedGoogle ScholarCrossref
19.
Elahi  M, Rakhshan  V, Ghasemian  NT, Moshref  M.  Prognostic value of transforming growth factor beta 1 [TGF-β1] and matrix metalloproteinase 9 [MMP-9] in oral squamous cell carcinoma.  Biomarkers. 2012;17(1):21-27.PubMedGoogle ScholarCrossref
20.
Singh  RD, Nilayangode  H, Patel  JB,  et al.  Combined evaluation of matrix metalloproteinases and their inhibitors has better clinical utility in oral cancer.  Int J Biol Markers. 2011;26(1):27-36.PubMedGoogle ScholarCrossref
21.
Liu  CJ, Chang  KW, Lin  SC, Cheng  HW.  Presurgical serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in oral squamous cell carcinoma.  Oral Oncol. 2009;45(10):920-925.PubMedGoogle ScholarCrossref
22.
Hsu  HW, Wall  NR, Hsueh  CT,  et al.  Combination antiangiogenic therapy and radiation in head and neck cancers.  Oral Oncol. 2014;50(1):19-26.PubMedGoogle ScholarCrossref
23.
Kilic  E, Schild  SE, Thorns  C, Bajrovic  A, Rades  D.  Prognostic role of vascular endothelial growth factor and its receptor-1 in patients with esophageal cancer.  Anticancer Res. 2014;34(9):5221-5226.PubMedGoogle Scholar
24.
Chen  M, Cai  E, Huang  J, Yu  P, Li  K.  Prognostic value of vascular endothelial growth factor expression in patients with esophageal cancer: a systematic review and meta-analysis.  Cancer Epidemiol Biomarkers Prev. 2012;21(7):1126-1134.PubMedGoogle ScholarCrossref
25.
Seibold  ND, Schild  SE, Bruchhage  KL, Gebhard  MP, Noack  F, Rades  D.  Prognostic impact of VEGF and FLT-1 receptor expression in patients with locally advanced squamous cell carcinoma of the head and neck [published correction appears in Strahlenther Onkol. 2014;190(3):324].  Strahlenther Onkol. 2013;189(8):639-646.PubMedGoogle ScholarCrossref
26.
Pan  J, Kong  L, Lin  S, Chen  G, Chen  Q, Lu  JJ.  The clinical significance of coexpression of cyclooxygenases-2, vascular endothelial growth factors, and epidermal growth factor receptor in nasopharyngeal carcinoma.  Laryngoscope. 2008;118(11):1970-1975.PubMedGoogle ScholarCrossref
27.
Parr  C, Watkins  G, Boulton  M, Cai  J, Jiang  WG.  Placenta growth factor is over-expressed and has prognostic value in human breast cancer.  Eur J Cancer. 2005;41(18):2819-2827.PubMedGoogle ScholarCrossref
28.
Wei  SC, Tsao  PN, Yu  SC,  et al.  Placenta growth factor expression is correlated with survival of patients with colorectal cancer.  Gut. 2005;54(5):666-672.PubMedGoogle ScholarCrossref
29.
Zhang  L, Chen  J, Ke  Y, Mansel  RE, Jiang  WG.  Expression of Placenta growth factor (PlGF) in non-small cell lung cancer (NSCLC) and the clinical and prognostic significance.  World J Surg Oncol. 2005;3:68.PubMedGoogle ScholarCrossref
30.
Escudero-Esparza  A, Martin  TA, Davies  ML, Jiang  WG.  PGF isoforms, PLGF-1 and PGF-2, in colorectal cancer and the prognostic significance.  Cancer Genomics Proteomics. 2009;6(4):239-246.PubMedGoogle Scholar
31.
Escudero-Esparza  A, Martin  TA, Douglas-Jones  A, Mansel  RE, Jiang  WG.  PGF isoforms, PLGF-1 and PGF-2 and the PGF receptor, neuropilin, in human breast cancer: prognostic significance.  Oncol Rep. 2010;23(2):537-544.PubMedGoogle Scholar
32.
Cheng  SJ, Lee  JJ, Kok  SH,  et al.  Expression of placenta growth factor: an independent factor for prediction of progression and prognosis of oral cancer.  Head Neck. 2010;32(10):1363-1369.PubMedGoogle ScholarCrossref
33.
Cheng  SJ, Lee  JJ, Cheng  SL,  et al.  Increased serum placenta growth factor level is significantly associated with progression, recurrence and poor prognosis of oral squamous cell carcinoma.  Oral Oncol. 2012;48(5):424-428.PubMedGoogle ScholarCrossref
34.
Gorugantula  LM, Rees  T, Plemons  J, Chen  HS, Cheng  YS.  Salivary basic fibroblast growth factor in patients with oral squamous cell carcinoma or oral lichen planus.  Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;114(2):215-222.PubMedGoogle ScholarCrossref
35.
Nakamura  T, Ozawa  S, Kitagawa  Y, Shih  CH, Ueda  M, Kitajima  M.  Expression of basic fibroblast growth factor is associated with a good outcome in patients with squamous cell carcinoma of the esophagus.  Oncol Rep. 2005;14(3):617-623.PubMedGoogle Scholar
36.
Hase  T, Kawashiri  S, Tanaka  A,  et al.  Correlation of basic fibroblast growth factor expression with the invasion and the prognosis of oral squamous cell carcinoma.  J Oral Pathol Med. 2006;35(3):136-139.PubMedGoogle ScholarCrossref
37.
Homer  JJ, Greenman  J, Stafford  ND.  Circulating angiogenic cytokines as tumour markers and prognostic factors in head and neck squamous cell carcinoma.  Clin Otolaryngol Allied Sci. 2002;27(1):32-37.PubMedGoogle ScholarCrossref
38.
Dietz  A, Rudat  V, Conradt  C, Weidauer  H, Ho  A, Moehler  T.  Prognostic relevance of serum levels of the angiogenic peptide bFGF in advanced carcinoma of the head and neck treated by primary radiochemotherapy.  Head Neck. 2000;22(7):666-673.PubMedGoogle ScholarCrossref
39.
Candau-Alvarez  A, Gil-Campos  M, De la Torre-Aguilar  MJ, Llorente-Cantarero  F, Lopez-Miranda  J, Perez-Navero  JL.  Early modification in drainage of interleukin-1β and tumor necrosis factor-α best predicts surgical-site infection after cervical neck dissection for oral cancer.  J Oral Maxillofac Surg. 2015;73(6):1189-1198.PubMedGoogle ScholarCrossref
40.
Kuropkat  C, Plehn  S, Herz  U, Dünne  AA, Renz  H, Werner  JA.  Tumor marker potential of serum matrix metalloproteinases in patients with head and neck cancer.  Anticancer Res. 2002;22(4):2221-2227.PubMedGoogle Scholar
Original Investigation
July 2017

Association of Oral Cavity and Oropharyngeal Cancer Biomarkers in Surgical Drain Fluid With Patient Outcomes

Author Affiliations
  • 1Division of Head and Neck Surgery, Department of Otolaryngology–Head and Neck Surgery, University of Minnesota, Minneapolis
  • 2Department of Otolaryngology–Head and Neck Surgery, Hennepin County Medical Center, Minneapolis, Minnesota
  • 3Division of General Internal Medicine, Department of Medicine, University of Minnesota, Minneapolis
  • 4Division of Biostatistics, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
JAMA Otolaryngol Head Neck Surg. 2017;143(7):670-678. doi:10.1001/jamaoto.2016.3595
Key Points

Question  Are wound fluid biomarkers in patients with oral cavity or oropharyngeal cancer associated with cancer prognosis?

Findings  In this cohort study of 20 adults after surgical extirpation, assays of wound fluid biomarkers indicated that levels of matrix metalloproteinases 1 and 3 and soluble fms-like tyrosine kinase 1 were associated with recurrence; vascular endothelial growth factor isoform A, with nodal metastasis; and basic fibroblast growth factor, with lymphovascular invasion. No biomarkers assayed showed a statistically significant association with disease-free survival.

Meaning  Measurement of biomarkers in surgical drain fluid potentially represents a novel means of assessing cancer prognosis in this population.

Abstract

Importance  Survival rates for head and neck cancer have been relatively stable for several decades. Individualized prognostic indicators are needed to identify patients at risk for poorer outcomes.

Objective  To determine whether biomarker levels in surgical drain fluid of patients with head and neck cancer are associated with poor cancer outcomes.

Design, Setting, and Participants  This prospective cohort study enrolled patients with squamous cell carcinoma (SCC) of the oral cavity and oropharynx who required surgical treatment from April 1, 2011, to February 1, 2016, at a tertiary or academic care center. Twenty patients, including 14 with stage IV disease, had complete specimen collection. Differences in cytokine and MMP levels by disease outcomes were evaluated.

Interventions  Patients underwent surgical treatment with drain placement as dictated by the standard of care. Drain fluid samples were collected every 8 hours postoperatively until drains were removed because of clinical criteria. Levels of cytokines and matrix metalloproteinases (MMPs) were measured using electrochemiluminescent, patterned array, multiplex technology.

Main Outcomes and Measures  The primary clinical outcome measures were survival outcome and recurrence. The biomarkers measured included the cytokines basic fibroblastic growth factor, vascular endothelial growth factor isoform A, soluble fms-like tyrosine kinase-1 (sFlt-1), and placental growth factor (PIGF) and MMP-1, MMP-3, and MMP-9. Other clinical and pathologic cancer characteristics were recorded.

Results  In this cohort of 20 patients with SCC (15 men and 5 women; mean [SD] age, 63.5 [9.9] years), a significant association with recurrence was found for levels of MMP-1 (relative difference between groups, 2.78; 95% CI, 1.23-6.29), MMP-3 (relative difference between groups, 5.29; 95% CI, 2.14-13.05), and sFlt-1 (relative difference between groups, 3.75; 95% CI, 1.84-7.65). No biomarkers were associated with disease outcome. Vascular endothelial growth factor isoform A was associated with nodal metastasis (relative difference between groups, 1.98; 95% CI, 1.12-3.51), and basic fibroblastic growth factor was associated with lymphovascular invasion (relative difference between groups, 1.74; 95% CI, 1.02-2.97).

Conclusions and Relevance  In this pilot sample of patients with SCC of the oral cavity and oropharynx, MMP-1, MMP-3, and sFlt-1 levels in wound fluid were associated with poor clinical cancer outcomes in the form of recurrence. This finding is consistent with the literature of tumor microenvironment in saliva, serum, and tumor tissue biomarkers. To our knowledge, this report is the first of such findings in surgical drain fluid, an easily accessible means of cytokine measurement. Measurement of these biomarkers in surgical fluid potentially represents a novel means of assessing cancer prognosis in this population.

×